We and others have reported the presence of novel progastrin (PG)/gastrin receptors on normal and cancerous intestinal cells. We had earlier reported the presence of 33-36 kDa gastrin-binding proteins on cellular membranes of colon cancer cells. The goal of the current study was to identify the protein(s) in the 33-36 kDa band, and analyse its functional significance. A carbodiimide crosslinker was used for crosslinking radio-labeled gastrins to membrane proteins from gastrin/PG responsive cell lines. Native membrane proteins, crosslinked to the ligand, were solubulized and enriched by >1000-fold, and analysed by surface-enhanced laser desorption/ ionization-time of flight-mass spectrometry. The peptide masses were researched against the NCBInr database using the ProFound search engine. Annexin II (ANX II) was identified, and confirmed by matrix-assisted laser desorption/ionization-time of flight-mass spectrometry. As HCT-116 cells express autocrine PG, the in situ association of PG with ANX II was demonstrated in pulldown assays. Direct binding of PG with ANX II was confirmed in an in vitro binding assay. In order to confirm a functional importance of these observations, sense and anti-sense (AS) ANX II RNA-expressing clones of intestinal epithelial (IEC-18) and human colon cancer (HCT-116) cell lines were generated. AS clones demonstrated a significant loss in the growth response to exogenous (IEC-18) and autocrine (HCT-116) PG. We have thus discovered that membrane-associated ANX II binds PG/gastrins, and partially mediates growth factor effects of the peptides.
Introduction
Progastrin and gastrin peptides are expressed in neuroendocrine cells in the brain and antral part of the stomachs and processed into the precursor peptide (PG) and glycine extended form of gastrins (GG); subsequent amidation at the C-terminal end generates amidated forms of gastrins (G17, G34) (Dockray et al., 1996) . Under physiological conditions, only processed forms of gastrins (G17, G34) are present as the major circulating forms of gastrins (Dockray et al., 1996) .
PG, GG and G17 exert proliferative effects on normal and cancerous gastrointestinal (GI) cells in vitro and in vivo (Wang et al., 1996; Hollande et al., 1997; Koh et al., 1999; Baldwin et al., 2001; Brown et al., 2003; Singh et al., 2003; Ottewell et al., 2005) . PG and GG exert cocarcinogenic effects on colon carcinogenesis in response to azoxymethane (Singh et al., 2000a, b; Aly et al., 2001; Cobb et al., 2004) . Elevated levels of circulating PG are measured in hypergastrinemia owing to various etiologies (including ZE syndrome and pernicious anemia) (Rengifo-Cam and Singh, 2004) , and in patients with colorectal cancer (CRC) (Siddheshwar et al., 2001) . As potent co-carcinogenic effects of PG are reported in Fabp-PG mice, that express 'patho-physiological' concentrations of hPG (0.1-5 nM) (Cobb et al., 2004) , it suggests that elevated levels of circulating PG, as measured in patients with hyperastrinemia and CRC, may play a role in colon carcinogenesis.
Besides circulating gastrins, autocrine gastrins (mainly PG), play an equally important role in maintaining growth and tumorigenic potential of gastrindependent tumors (Singh et al., 1996; Hollande et al., 1997; Rengifo-Cam and Singh, 2004) . Recent studies further highlight an important role of colon cancerassociated oncogenic pathways (mutant Ras and Wnt/ b-catenin) in upregulating the gastrin gene expression in CRCs (Lei et al., 2004; Chakladar et al., 2005) .
We now know that increased proliferation and decreased apoptosis contributes to the growth factor and co-carcinogenic effects of PG-like peptides (Wu et al., 2000 (Wu et al., , 2003 Singh et al., 2003; Rengifo-Cam and Singh, 2004) . Several receptor (R)-subtypes bind gastrin and choecystokinin octapeptide (CCK)-like peptides. Cholecystokinin type 1 receptor (CCK 1 R) mainly bind CCK-like peptides and have negligible affinity for gastrins (Kopin et al., 1992; Wank et al., 1992) . Cholecystokinin type 2 receptor (CCK 2 R) bind amidated gastrins and CCK with almost equal affinity, but demonstrate negligible affinity for non-amidated gastrins (Kopin et al., 1992) . Low-affinity gastrin-binding sites (K d ¼ B1.0 mM) termed CCKC-R bind PG and gastrins (Zhang and Baldwin, 1994) . High-affinity binding sites (receptors?) were identified that were distinct from CCK 1 R, CCK 2 R and CCKC-R (Chicone et al., 1989; Narayan et al., 1992; Seva et al., 1994; Singh et al., 1995 Singh et al., , 2003 Baldwin et al., 2001) . These novel binding sites remain unidentified to-date. Based on the pharmaco-kinetics of the various receptors/binding proteins, CCK 2 R can mediate biological effects of only CCK and gastrins, whereas the high-affinity PG binding sites (PG-R?) can mediate biological effects of PGs and gastrins at concentrations measured in the circulation of patients with hypergastrinemia and CRC (reviewed in Rengifo-Cam and Singh, 2004) .
In order to understand the cellular mechanisms by which PG and gastrin-like peptides exert growth factor effects on target cells, it is critical that the novel PG/ gastrin-binding protein(s) are identified. Thus, the goals of the current study were to identify the high-affinity membrane proteins on the PG/gastrin responsive cell lines, that lack the expression of high-affinity CCK-R, and confirm the functional role of the identified protein(s) in mediating the growth factor effects of PG. Previously, we had identified the presence of B33-36 kDa gastrin-binding proteins (GBPs) on cellular membranes of colon cancer cells, that were specific for binding gastrin-like peptides, with very low affinity for CCK-like peptides (Chicone et al., 1989 ). In the current study, we improved the methods of crosslinking, solubilization and enrichment of the B32-36 kDa GBPs, followed by identification by surface-enhanced laser desorption/ionization-time of flight-mass spectrometry (SELDI-TOF-MS) and matrix-assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS). As a result of these investigations, we discovered that Annexin II (ANX II) represents the high-affinity 32-36 kDa gastrin/PG binding protein. In order to examine the physiological relevance of this unexpected finding, the physical association of ANX II with PG was confirmed in situ and in vitro. A possible role of ANX II in mediating growth factor effects of PG was determined by downregulating the expression of ANX II using the antisense (AS) strategy. Our studies strongly suggest that membrane-associated ANX II binds PG and gastrins, and partially mediates growth factor effects of these peptides on target cells.
Results

Identification of gastrin responsive cell lines
We and others have previously reported the expression of gastrin gene by human and mouse colon cancer cells (reviewed in Rengifo-Cam and Singh, 2004) ; data from some of these cell lines can be found in Supplementary material (Supplementary Table 1 ). Downregulation of gastrin gene expression results in either complete loss, significant loss, slight loss, or no effect on the in vitro growth of the cells (Singh et al., 1996; Rengifo-Cam and Singh, 2004) . These results suggested that whereas some colon cancer cell lines (Colo-320) are extremely dependent on autocrine gastrins for continued proliferation, others were either not dependent (Colo-205A) or variably dependent (CA, HCT-116, DLD-1) (Supplementary Table 1 ). In the current study, we examined whether these cell lines were responsive to exogenous gastrins, in relation to gastrin gene expression. Representative data from growth assays with one of the cell lines, Colo-320, are presented in Figure 1 . PG was relatively more effective than G17 in stimulating the anchorage-dependent ( Figure 1a ) and anchorage-independent ( Figure 1b ) growth of Colo-320 cells, especially at 0.1 nM. Essentially similar results were obtained with cancer (CA) cells (data not shown). All other colon cancer cell lines (Supplementary Table 1) were negligibly responsive to exogenous gastrins. In the case of IEC cells, PG was significantly more effective than G17 in stimulating the growth of the cells, especially at lower concentrations, as previously reported .
Results of the growth assays suggested that cell lines expressing significant levels of autocrine gastrins (HCT-116, DLD-1) were generally refractory to the growth effects of exogenously added gastrins (Supplementary  Table 1) . Surprisingly, however, CA cells in spite of expressing significant levels of autocrine gastrins (Supplementary Table 1 ) were highly responsive to growth effects of exogenous gastrins, suggesting perhaps that CA cells express high levels of GBPs, thus allowing the cells to respond to both autocrine and exogenous gastrins. In the case of cell lines that expressed negligible to low levels of autocrine gastrins, the cells were either highly responsive (Colo-320), or demonstrated no significant response (Colo-205A, HT-29) (Supplementary Table 1 ). These results suggest that relative expression of GBPs and autocrine gastrins dictate the response of the cells to exogenously added gastrins. Cell lines that demonstrated a significant response to exogenously added gastrins (Colo-320, CA, IEC-18, Swiss 3T3), irrespective of the level of expression of autocrine gastrins, were selected for further characterization of GBPs.
Expression of CCK 2 R and high-affinity binding sites for PG-like peptides (PG-R) on colon cancer cells None of the human colon cancer cell lines examined by us, including HCT-116 and Colo-320, expressed CCK 2 R or CCKC-binding sites, when measured by either reverse transcription-polymerase chain reaction (RT-PCR) or real-time quantitative RT-PCR (Supplementary Figure 1 ).
On the other hand, we and others have reported the presence of high-affinity gastrin/PG preferring binding sites on a number of cell lines that are responsive to exogenous PG/G17. For example high-affinity (K d ¼ B1.0 nM) binding sites for PG are present on IEC and Swiss 3T3 cells, that demonstrate a relative binding affinity (RBA) for gastrins in the order of PG>G17>CCK8 (Singh et al., 1995 . The binding affinity of PG for colon cancer cells was determined by Scatchard analysis, and the RBA of gastrin-like peptides for the PG binding sites determined. Representative data from CA cells are presented in Figure 2 . CA cells were positive for 20-30 fmol of high-affinity (K d ¼ B1.7 nM) recombinant human progastrin (rhPG) binding sites/10 6 cells ( Figure 2a ). The RBA of the gastrin binding sites on CA cells was highest for PG, followed by G17 and appeared to be negligible for CCK-8 (Figure 2b ). The binding affinity data from different cell lines are presented in Supplementary Table 2 .
Data as presented in Figure 2 and Supplementary Table 2, confirm the presence of high-affinity binding proteins (GBPs) for gastrins on gastrin responsive colon cancer and intestinal/fibroblast cell lines, which were distinct from CCK 2 R and the low-affinity CCKC-R. In order to further characterize and identify these novel PG preferring binding proteins/receptors, the molecular mass (M r ) of the proteins was determined.
M r of membrane-associated GBPs: effect of crosslinker and pH Previously we had used the amino crosslinker, disuccinimidyl suberate (DSS), for crosslinking G2-17 to membrane proteins and reported the presence of B33, B45 and B80 kDa GBPs on normal colonic mucosal membranes (Narayan et al., 1992) , and the predominant presence of 33-36 kDa proteins on CA tumor membranes (Chicone et al., 1989) . In the current studies, we further refined the process, and used the carbodiimide crosslinker (EDC) for crosslinking G1-17 to the membrane binding proteins, in the presence or absence of bovine serum albumin (BSA) at pH ranging from 4.5 to 8.0. Representative data with CA tumor membranes are presented in Figure 3a I-G17 with EDC to the B33, B45 and B80 kDa membrane binding proteins was most effective at pH 6.0-6.5; at lower pH, specific binding to B33 and B45 kDa proteins was either lost or accentuated, respectively (Figure 3b) . At pH 7.0 and higher, specific binding to all three bands of proteins was lost (data not shown).
M r of GBPs, crosslinked to G1-17 with EDC, before or after solubilization Swiss 3T3, Colo-320 and CA tumors were all positive for the three molecular forms of GBPs, arbitrarily Representative images of colonies growing in agar, in response to the indicated concentrations of the peptides, are presented at Â 10 magnification. The number of colonies measured in response to 1.0 nM PG were arbitrarily assigned a 100% value, and the numbers measured in all other dishes are presented as a % of that (as numerically indicated on top of the dishes). *The number of colonies were significantly higher in response to 0.1 nM PG vs 0.1 nM G17 (Po0.05, n ¼ 6); colonies smaller than that indicated by the arrows were not counted. A similar spread of colony sizes were present in the PG vs G17-treated groups for the indicated doses. labeled a, b and c (Figure 4) . We obtained B0.5-1.0 mg of membrane proteins from 0.5-1.0 g of tumors. Using the optimally effective detergent buffer (CHAPS and CHS), B500 mg of proteins were solubilized from 10-20 mg of membrane proteins, resulting in an enrichment of >20-fold upon solubilization of GBPs, and a significant increase in the detection of GBPs in solubilized vs membrane-associated samples (Figure 4a and b). On solubilization, GBPs in bands b and c retained 70-100% specificity for radio-labeled G17, whereas GBPs in band a lost affinity for I rhPG in the presence or absence of increasing concentrations of either CCK8, G17 or rhPG and RBA calculated. Each point represents the mean values of triplicate measurements from a single experiment, and is representative of three similar experiments. The intraexperimental variation for each data point was o5%. The RBA calculated for each peptide is presented in a tabulated form in Supplementary  Table 2 .
Annexin II binds progastrin P Singh et al in Figure 5a . The various steps of solubilization, gel elution and concentration resulted in >2000-fold enrichment of GBPs, compared to that present on tumor membranes, resulting in the detection of proteins crosslinked to 125 I-G17, as seen from the corresponding autoradiogram ( Figure 5a ).
Identification of proteins in band c by SELDI-TOF-MS and MALDI-TOF-MS analysis
Proteins in band c ( Figure 5a ) were arbitrarily divided into two halves ( Figure 5b ). The information from peptide mapping and database search was definitive from both SELDI and MALDI analysis and identified 10 3 )-fold. Based on the data with 100-fold excess competing peptide, the RBA of GBPs in bands b and c appeared to be in the order of PG >GG>G17>CCK, which resembled the pattern previously reported for PG-R on IEC cells .
Annexin II binds progastrin P Singh et al ANX II in both the halves of band c. No other proteins were identified in band c, which appeared to be a homogenous band of ANX II proteins. Identification of ANX II as a possible binding protein (receptor?) for PG-like peptides was unexpected. An interaction of autocrine PG with the monomeric 36 kDa ANX II molecules, in situ, was confirmed in pulldown assays with anti-PG-antibodies (Abs) using HCT-116 cellular lysates, followed by Western immunoblot (WB) analysis with anti-ANX II Abs (Figure 5c ). The binding of PG with ANX II was further confirmed in vitro as described below.
ANX II binds rhPG in solution, in an in vitro binding assay The efficacy of anti-PG-Abs and anti-ANX II-Abs for immunoprecipitating the respective peptide/protein in solution was examined. Both the Abs effectively immunoprecipitated (IP) 60-70% of the respective peptide/protein in solution (Figure 6a and b) . In the next set of experiments, rhPG and ANX II were added either separately (lanes 1 and 2 in Figure 6c Figure 6c ) or anti-ANX II Abs (lower panel, Figure 6c ). The results provided the first direct evidence that rhPG and ANX II bind in solution and are co-IP by both Abs (Figure 6c ). The co-IP rhPG and ANX II were further visualized by Coomassie blue staining (Figure 6d) . Surprisingly, rhPG in solution appeared to be unstable and an additional 7 kDa band was evident in lanes 1 and 2 ( Figure 6d) ; the 7kDa band was more evident in lane 2, as the concentration of rhPG was B10 Â higher in lane 2 vs lane 1.
RBA of Tenascin-C for binding PG binding sites ANX II was identified as a receptor protein for tenascin-C (TN-C) (Chung and Erickson, 1994) . A splice variant fragment of TN-C, TNfnA-D, had the highest binding affinity for ANX II (Chung and Erickson, 1994) . Annexin II binds progastrin P Singh et al Table 1 . The RBA of TN-C for PG binding sites was either slightly higher ( Figure 7a , Table 1 ), or slightly lower ( Figure 7b , Table 1 ), than that of rhPG, suggesting that at least 50-60% of the specific binding sites for rhPG and TN-C are similar on the ANX II molecule. Surprisingly, 40% of the specific binding of PG could not be displaced by even 10 000-fold excess of TN-C, suggesting that B40% of the PG-binding sites were specific for PG-like peptides, and were not shared with TN-C.
Downregulation of ANX II expression significantly reduces the growth factor effects of PG Clones of IEC-18 and HCT-116 cells were generated, that either expressed the truncated ANX II protein (S or control clones) or were downregulated for the expression of ANX II (AS clones). The relative expression of ANX II in representative sense (S) and AS clones compared to that in the wild-type IEC-18 cells (C) is presented in Figure 8a . The relative levels of ANX II in C cells were similar that in the S clones, for reasons described in Materials and methods. The AS clones demonstrated a significant loss in the relative expression of ANX II (Figure 8a) . A representative IEC-18 clone (AS 2 ) demonstrated a significant loss (>70%) in its growth response to optimal doses of PG (0.1-1.0 nM), compared to the growth response of S 2 (control) clones (Figure 8b ). The growth response of AS 2 and S 2 clones to 1% fetal calf serum (FCS), however, was similar; suggesting that the effects of downregulation of ANX II were specific to PG. In order to confirm a receptor-like role of ANX II for mediating the growth factor effects of PG, the wild-type (parental) IEC-18 cells were pre-treated with either pre-immune IgG or anti-ANX II-Ab, at two different dilutions, followed by measuring the growth response of the cells to either an optimal dose of PG (0.1 nM) or 1% FCS (Figure 8c ). The pre-treatment of the cells with the anti-ANX II-Ab (especially at the lower dilution), significantly decreased the growth response of the cells to PG, but not to FCS, providing strong evidence that ANX II may indeed function as a receptor protein for PG/gastrin-like peptides. A possible role of ANX II in mediating growth effects of autocrine PG was examined in HCT-116 cells. AS-HCT-116 clones were downregulated for the expression of ANX II by B90% (Figure 9a) , confirming a significant sequence homology between rat and human ANX II cDNA. Surprisingly, a few S clones (such as S 7 , Figure 9a ) demonstrated an increase in the expression of ANX II compared to that measured in non-transfected cells (C), for reasons unknown. As proof of principle, the overexpressing S 7 clone was chosen for the growth studies. As HCT-116 cells express significant levels of autocrine PG and are non-responsive to exogenous PG (Supplementary Table 1) , the growth of the clones was measured in response to FCS. FCS dose-dependently increases autocrine expression of gastrin gene (and hence PG), and thus the response to FCS has been used as an indirect means of measuring response to autocrine PG (Singh et al., 1996) . The growth response of nontransfected (control) HCT-116 cells to increasing concentrations of FCS is shown in Figure 9b . The AS-ANX II-HCT-116 clones demonstrated a significant loss in the growth response by B70-80%, in the presence or absence of FCS (Figure 9c and d) . The overexpressing S 7 clones (Figure 9e) , demonstrated an enhanced response to FCS, especially at higher concentrations. The relative levels of PG in the cellular lysates of the cells (measured as described previously, Cobb et al., 2004) were similar in the S 7 , AS 2 and AS 3 clones, compared to that in the C cells (Supplementary Table 3) , and increased similarly in all the S, AS and C clones, in a dose-dependent manner, in response to FCS, as published previously (Singh et al., 1996) ; these results suggest that endogenous ANX II likely plays an important role in mediating growth factor effects of autocrine PG. Table 1 . Each point in the graph represents a mean value of triplicate measurements from a single experiment, and is representative of two similar experiments. The intraexperimental variation for each data point was o10%. In both cell lines, TNfnA-D only displaced B60% of the specific binding of 125 I rhPG, even at very high concentrations (10 mM). (Singh et al., 1996) . As ANX II associates with cellular membranes, either as a monomer (B33-36 kDa) or as a heterotetramer (AIIt) (two units of S100A or p11 and two units of ANX II; Hajjar and Acharya, 2000) , we confirmed that the monomeric 36 kDa ANX II binds PG in an in vitro binding assay, strongly suggesting that ANX II can function as a membrane 'receptor' for PG/G17 peptides.
Physiological relevance of binding of ANX II with PG was obtained in experiments with AS-ANX II clones of cells, responsive to either exogenous (IEC-18, Singh et al., 2003) or autocrine (HCT-116, Singh et al., 1996) PG. Our results suggest that ANX II expression is required for mediating B50% of the growth effects of exogenous PG on intestinal (IEC) cells. Results with anti-ANX II Abs further confirms a possible important role of ANX II as a receptor-like protein for PG/gastrinlike peptides. Additionally, the growth of AS-ANX II-HCT-116 clones was decreased by >70-80%, and phenocopied the loss of growth of AS-gastrin-HCT-116 clones, as previously reported (Singh et al., 1996) . These results strongly suggest that the growth factor effects of autocrine PG are attenuated by >80% on downregulation of ANX II expression. The results further highlighted the possibility that ANX II may play a predominant role in mediating growth factor effects of autocrine PG in colon cancer cells, whereas other proteins, besides ANX II, may be required for mediating 100% of the growth factor effects of PG/ gastrins on non-tumorigenic (normal) cells such as IEC-18. IP ANX II is a multifunctional protein (Raynal and Pollard, 1994) , which binds acid phospholipids and actin with significant affinity (Gerke and Moss, 2002) . ANX II is cleaved by chymotrypsin into a 33 kDa C-terminal core domain and a 3 kDa N-terminal domain of 30 amino acids. The first 14 residues of the N-terminal domain contains a high-affinity binding site for S100A10, a Ca 2 þ binding protein (M r 11K) (Waisman, 1995) . Majority of ANX II is tightly associated with p11 forming an ANX II 2 /p11 2 heterotetramer (AIIt). ANX II is expressed abundantly in rejuvenating cells (fibroblasts, endothelial cells, epithelial cells of the lung and GI tract) (Frohlich et al., 1990) , and is expressed maximally during S phase and promotes DNA synthesis and cell proliferation (Chiang et al., , 1999 . ANX II expression is increased in many human cancers (Frohlich et al., wild type (C) cells were not transfected. The S clones, for reasons described in Materials and methods, expressed almost similar levels of ANX II compared to C cells. The AS clones were downregulated for the expression of ANX II by >70%. The total number of specific high-affinity binding sites for PG (measured by a single point assay, as described previously (Singh et al., 1995) , were significantly reduced by B65-78% in AS-ANX II clones compared to that in C cells and S clones (data now shown). (b) The representative S 2 and AS 2 clones were stimulated to grow in the presence of optimal concentrations of rhPG (0.1, 1.0 nM). FCS (1%) was used as a positive control, and no simulation as a negative control. The growth assays were conducted as described in Methods. Each bar graph represents mean of six observations from a single experiment and is representative of two similar experiments. (c) Effect of anti-ANX II-Abs on the growth of IEC-18 cells in response to PG. The parental IEC-18 cells in culture were pretreated with similar concentrations of either anti-ANX II-Abs or pre-immune IgG (control), for 2 h at RT at the indicated dilutions, by our published methods (Singh et al., 1994b) , followed by the treatment with either 0.1 nM rhPG or 1% FCS as described above. Each bar graph represents mean of four observations from a single experiment and is representative of two similar experiments.
Annexin II binds progastrin P Singh et al 1990; Tanaka et al., 2004) , and downregulation of its expression results in the loss of proliferation (Chiang et al., 1999, current studies) . All these studies thus strongly suggest that ANX II is a key regulator of DNA synthesis and cell proliferation. Highaffinity binding sites for PG (ANX II) are present on colonic and intestinal epithelial cells Singh et al., 2003; Rengifo-Cam and Singh, 2004) and colon cancer cells (current studies), but are absent in the brain or liver (unpublished data from our laboratory), which agrees with the reported expression of ANX II (PG 'receptor'), primarily in proliferating cells (Frohlich et al., 1990; Chiang et al., 1993) . Cellular functions of ANX II are regulated by posttranslational modifications and cellular localization.
ANX II residues Tyr 23 and Serines 11 and 25 are phosphorylated by c-Src and PKC, respectively (Gould et al., 1986) , after activation of either insulin receptor (R), or platelet-derived growth factor-R (Brambilla et al., 1991; Biener et al., 1996) . ANX II may thus function as a second messenger for transduction of extracellular signaling pathways. Our current studies suggest that PG/gastrins bind membrane-associated ANX II, which perhaps leads to colocalization and activation of ANX II and c-Src kinase. The latter possibility is highlighted by the fact that PG/gastrins activate c-Src kinase in target cells (Singh et al., 1994c; Brown et al., 2003; Ferrand et al., 2005) .
Our studies demonstrate that monomeric ANX II functions as a high-affinity 'receptor' protein for S and AS clones of HCT-116 cells were generated. (a) Representative WB data from S and AS clones demonstrating relative levels of ANX II expression, compared to that in the control (C) cells is presented. Other than S 7 clones, all other S clones did not overexpress ANX II. All AS clones were significantly downregulated for the expression of ANX II by >80-90%. In previous studies, we have demonstrated that the expression of autocrine PG in HCT-116 cells is increased in a dose-dependent manner in the presence of FCS (Singh et al., 1996) , as the gastrin gene promoter contains serum response element and is specifically upregulated in the presence of FCS (Rengifo-Cam and Singh, 2004) . In the current studies, we confirmed that the relative levels of PG in the AS and S clones increased in a dose-dependent manner in response to increasing concentrations of FCS, similar to that measured in the control cells (Supplemental Table 3 ). The growth response of the control (HCT-116-C) cells to increasing concentrations of FCS is presented in (b). The growth response of two representative AS clones is presented in (c and d) . The growth response of S 7 clone, that was overexpressing ANX II for reasons unknown, is presented in (e). Each bar graph represents data from 4-6 observations from a single experiment, and is representative of two similar experiments. * ¼ Po0.05 vs corresponding HCT-116-C values.
Annexin II binds progastrin P Singh et al PG/gastrins. ANX II has previously been described as a high-affinity receptor for the extracellular matrix protein TN-C (Chung and Erickson, 1994) , and as a co-receptor on endothelial cells for tissue plasminogen activator, plasminogen and plasmin (Hajjar and Acharya, 2000) . AIIt was identified as a receptor for plasmin-induced signaling in human peripheral monocytes, which involved the activation of nuclear factor (NF)-kB, JAK/ signal transducers and activators of transcription (STAT) and p38 mitogen-activated protein kinase (MAPK) signaling cascades, leading to a full-scale proinflammatory response (Laumonnier et al., 2006) . It is possible, that binding of PG to ANX II may mediate an activation of a similar cascade of signaling molecules in target cells, as we and others have reported activation of Src, phosphatidylinositol 3 0 -kinase/Akt, JAK2, STAT5/3, extracellular signal-regulated kinases, p38 MAPK and NFkB, in response to PG Brown et al., 2003; Ferrand et al., 2005; Rengifo-Cam and Singh, 2005) . Importantly, our preliminary findings suggest that treatment of IEC-18 cells with anti-ANX II-Abs results in attenuating the activation of many of the above-described signaling molecules, in response to PG (unpublished data from our laboratory).
At mild acidic pH, AIIt undergoes conformational changes similar to those induced by Ca 2 þ . Thus, ANX II appears to have access to the hydrophobic part of the cellular membranes at both acidic pH in the absence of Ca 2 þ and at neutral pH in the presence of Ca 2 þ (Lambert et al., 2004) . This may explain our findings of a significant increase in the crosslinking of gastrins to ANX II (B32-36 kDa) at slightly acidic pH (Figure 3b ). The 36 kDa ANX II protein, bound to radio-labeled TNfnA-D, was generally seen as a doublet band in SDS-PAGE (Chung and Erickson, 1994) . In freshly prepared membrane extracts, the authors frequently saw a single band of 36 kDa; two lower molecular weight bands appeared at later times (Chung and Erickson, 1994) . The authors concluded that as ANX II has two protease cleavage sites near the NH 2 terminus, it likely produces 2-3 closely spaced bands on SDS-PAGE on binding with the ligand such as TN-C (Chung and Erickson, 1994) . In the current studies, we also observed the presence of a wide band of 32-36 kDa proteins crosslinked to radio-labeled gastrins ( Figure 5 ), all of which were identified as ANX II by SELDI-TOF-MS. However, in the in vitro experiments, in the absence of cell-associated proteases, only a single band of 36 kDa ANX II co-IP with PG ( Figure 6 ). ANX II expression is upregulated in fibroblasts transformed by v-H-ras, v-src and v-mos (Ozaki and Sakiyama, 1993) , and in cells treated with mitogenic or trophic factors such as epidermal growth factor (EGF), fibroblast growth factor, nerve growth factor or transforming growth factor (TGF)-b1 (Keutzer and Hirschhorn, 1990) . Upregulation of ANX II was also discovered in gastric epithelial cells infected with Helicobacter pylori (Das et al., 2005) . At the same time, H. pylori infection of gastric mucosa, and growth factors such as EGF and TGF-b1 have been reported to increase the expression of gastrin gene, directly or indirectly (Lei et al., 2004; Rengifo-Cam and Singh, 2004) . These findings suggest the intriguing possibility that the direct (EGF, TGF-b1, oncogenic K-ras) and indirect (H. pylori) growth effects of these agents may be magnified by an upregulation of both the gastrin gene (PG) and its binding 'receptor' protein, ANX II.
Overexpression of ANX II and TN-C proteins was measured in a high percentage of CRC, and appeared to correlate with tumor size, depth of invasion and pTNM stage (Emoto et al., 2001) . Interestingly, treatment of human astrocytoma U373 cells with gastrin resulted in overexpression of TN-C and S100A6 (Kucharczak et al., 2001) . As c-Jun and NF-kB synergistically transactivate TN-C promoter in primary rat embryo fibroblasts (Mettouchi et al., 1997) , gastrin may activate TN-C promoter in glioblastoma cells via the same signaling molecules known to be activated in response to PG/ gastrins in other cells (Ferrand et al., 2005; RengifoCam and Singh, 2005) .
Purified ANX II binds TNfnA-D and native TN-C at nanomolar concentrations (Chung and Erickson, 1994) .The results of our current studies suggest that PG binds ANX II at the TN-C binding site, either with a significantly higher binding affinity, or equivalent affinity ( Figure 7) ; however, only 60% of the binding sites appear to be common suggesting that either PG binds other proteins besides ANX II or it binds additional binding sites on ANX II that are not displaced by TN-C.
The large TN-C splice variant, containing TNfnA-D, is generally expressed in tissues undergoing active cellular migration or tissue remodeling (Chung and Erickson, 1994) . Transformed fibroblasts and fetal lung tissues express TN-C with the A-D domains (Oyama et al., 1991) . It thus appears likely that the splice variant may facilitate cell migration/invasion and tissue remodeling possibly through binding to ANX II with high affinity (Chung and Erickson, 1994) . Based on the literature described above and our current findings, we hypothesize that in the absence of expression of the splice variant form of TN-C, PG likely binds ANX II with a significantly higher binding affinity and dictates the functions of ANX II towards cellular proliferation and progression of the disease. However, on expression of the TN-C splice variant, which may occur during advanced stages of the CRC disease, the splice variant may bind ANX II with equivalent affinity and cocontribute to the functions of ANX II along with PG. Future studies in this field should help to dissect the relative contribution of ANX II, splice variant of TN-C and autocrine PG in the proliferation and metastasis of CRC cells.
Material and methods
Cell culture
Cell lines used in this study include a mouse fibroblast cell line (Swiss 3T3), a normal rat intestinal epithelial cell line (IEC-18), a mouse colon cancer cell line (CA), and human colon cancer cell lines . The cell lines were obtained and grown as monolayer cultures in the appropriate growth medium, and regularly monitored for the absence of mycoplasma as described previously (Singh et al., 1995 (Singh et al., , 1996 . Stock cultures of cells were subcultured at appropriate intervals to maintain the cells at subconfluent densities. For cell counting and subculturing, the cells were dispersed with 0.05% trypsin and 0.02% ethylene diaminetetraacetic acid (EDTA).
Growth assays
The anchorage-dependent growth assays were conducted as described previously (Singh et al., 1995 (Singh et al., , 1996 . Generally, quiescent cells were stimulated with or without various doses of the peptides for 48-72 h in serum-free medium, and the cell numbers measured directly or indirectly in a cell count on an 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetrazolium bromide assay, as described previously (Singh et al., 1995 (Singh et al., , 1996 . A soft agar colonogenic assay was conducted for measuring anchorage-independent growth of the cells, as described previously (Singh et al., 1996) . The total number of colonies/well were counted with the help of an inverted light microscope (Nikon, Houston, TX, USA).
Methods used for RT-PCR analysis of cellular RNA for hCCK 2 R and CCKC binding proteins, and real-time quantitative PCR for measuring CCK 2 R in human and mouse colon cancer cell lines are provided as Supplementary Method 1.
Binding affinity and RBA of peptides for 125 I rhPG binding sites The full-length recombinant human PG 1-80 (rhPG) was generated in an Escherichia coli expression system and purified and confirmed as described previously . rhPG was radio-labeled with Na 125 I (Amersham, Chicago, IL, USA), and the intact 125 I-rhPG purified by high-pressure liquid chromatography as described previously . For these experiments, cells were expanded in vitro in 175 mm flasks and grown to subconfluence in the indicated growth medium containing 10% FCS. All binding assays were performed 36-48 h after seeding the cells in culture medium containing 10% FCS and 2% glutamine. Before the start of the binding assays, the cells in culture were washed with Hanks balanced salt solution (HBSS) (Gibco, Carlsbad, CA, USA) containing 0.1% BSA and 25 mM N-2-hydroxyl piperazine-N 0 -2-ehane sulfonic acid (HEPES) (Sigma, St Louis, MO, USA) and scraped with a rubber policeman into conical tissue culture polystyrene tubes. Cells were centrifuged at 500 g for 5 min and resuspended in HBSS at a concentration of 2 Â 10 6 cells/ml. Aliquots (B1.0 ml) of suspended cells in polystyrene tubes were used in the binding assays. Binding assays were conducted as described previously (Singh et al., 1995 . For purposes of determining binding affinity, a multipoint (7-12 points) saturation analysis was performed by using increasing concentrations (0.03-1.0 nM) of 125 I-rhPG without (total binding) or with (nonspecific binding) 1000-fold excess of radio inert rhPG. The binding data were analysed by a Scatchard plot (Scatchard, 1949) . Binding assays were performed at 371C for 30-60 min at pH 6.5 (optimal for all the cell lines). In order to define the RBA of various peptides for the PG-binding sites on the cells, cells in suspension were incubated with 1.0 nM 125 I-rhPG in the presence or absence of increasing concentrations (0.1 nM-10.0 mM) of either the homologous or heterologous peptide. Nonspecific binding was determined in the presence of 1000 Â excess of the nonlabeled homologous peptide. At the end of the incubation, the cells were pelleted and washed twice with 1 ml of fresh ice-cold HBSS plus 0.1% BSA. Cell pellets were counted for 125 I in a gamma counter with B70% efficiency for 125 I. The RBA of gastrin-like peptides and/or competing peptides for binding the specific binding sites for rhPG were determined from a logdose inhibition of specific binding of 125 I-rhPG by various peptides as described previously (Singh et al., 1995 . As reported previously (Singh et al., 2003), 125 I-rhPG was quite unstable, and therefore all binding assays had to be completed within a day of labeling the peptide.
M r of GBPs, before or after solubilization Crude membranes from tumors or cells were used for the determination of M r of the GBPs as described previously (Chicone et al., 1989; Narayan et al., 1992) . Briefly, in order to prepare crude membranes from tumors, colon cancer cells (CA, Colo-320) and Swiss-3T3 cells were grown in either balb/ c mice (CA) or nude mice (Colo-320, Swiss 3T3) as described previously (Singh et al., 1987 (Singh et al., , 1995 . The tumors were harvested, and crude membranes prepared from the frozen tumors as described previously (Chicone et al., 1989; Narayan et al., 1992) . Crude membranes were also prepared from cells in culture, by published methods (Singh et al., 1995) . The crude membranes were then subjected to a binding assay with the indicated radio-labeled gastrin peptide (that were more stable than radio-labeled rhPG), in the presence or absence of 1000-fold excess non-labeled homologous gastrin peptide, as described previously (Chicone et al., 1989; Narayan et al., 1992; Singh et al., 1995) . The radio-labeled gastrin peptide bound to the GBPs on the crude membranes was then crosslinked with either the amino crosslinker, DSS (Sigma), as described previously (Chicone et al., 1989; Narayan et al., 1992; Singh et al., 1995) , or with the water-soluble EDC as described below. In a few experiments, intact cells in culture were also used as a substrate for crosslinking the radio-labeled peptide to the GBPs on cellular membranes, as described previously (Singh et al., 1995) . DSS was dissolved in Me 2 SO (dimethylsulfoxide (DMSO)), immediately before the use and added to the substrate to give a final concentration of 0.1% DMSO in the HBSS buffer containing phenylmethylsulfonyl fluoride (PMSF), as described previously for Swiss-3T3 cells (Singh et al., 1995) .
EDC, unlike DSS, catalyses the formation of amide bonds between carboxylic acids and amines to form O-acylurea, in the presence of N-hydroxysulfosuccinimide (HOSu[SO 3 ]) as a helper reagent (Staros et al., 1986) . In preliminary studies, we established that 20 mM EDC and 5 mM HOSu(SO 3 ) were maximally effective for crosslinking the radio-labeled gastrin peptide to crude membranes and intact cells. The major advantage of using EDC as a crosslinker was that the intact radio-labeled gastrin peptide, G17, could be used because the gastrin peptide has several Glu moieties. Additionally, EDC unlike DSS is water soluble and was thus dissolved directly in the binding buffer. Additionally, as DSS is an amino crosslinker, G17, which is blocked at the N-terminus, could not be used and instead radio-labeled G2-17 with a free N-terminus was used. I-G2-17 were prepared and purified as described previously (Chicone et al., 1989; Narayan et al., 1992; Singh et al., 1995) . Aliquots of membranes/cells, radio-labeled with the indicated peptide, were either crosslinked with DSS or EDC þ HOSu (SO 3 ), for 15 min at 221C in the binding buffer containing 1 mM PMSF, in the presence or absence of 1% BSA. The reaction was terminated by rapid centrifugation. The membrane and cellular substrates were washed with excess binding buffer, devoid of BSA, and solubilized by boiling at 1001C for 3-5 min in 0.2 M Tris-HCl buffer, pH 6.8, containing 6% sodium dodecyl sulfate (SDS w/v) 2 mM EDTA, 10% glycerol, v/v, in the presence of 4% b-mercaptoethanol (v/v). The supernatant was then subjected to SDS-PAGE as described previously (Chicone et al., 1989; Narayan et al., 1992; Singh et al., 1995) . The gels were stained, destained, dried and exposed to Kodak XAR-5 film for approximately 7 days at À701C and the autoradiograms scanned using a laser densitometer.
In order to improve the yield of the crosslinked membrane binding proteins, the native membrane proteins were solubilized with non-ionic and ionic detergents, and the binding of the solubilized proteins with radio-labeled gastrin peptides were examined. In preliminary studies, several detergents were used, including Triton X-100 (Sigma), zwitterionic detergent, 3 [(3-cholamidopropyl)-dimethylammonio]-1-propane sulfonate (CHAPS) (CAL BIOCHEM Logolas, CA, USA), octyl bglucoside (OBG) and cholesteryl hemisuccinate ester (CHS) (Sigma) by published methods (Ginsberg et al., 1978; Gould et al., 1981; Naldini et al., 1990) . Briefly, membranes prepared from tumors/cells (as described above), were reconstituted in HEMGI buffer (20 mM HEPES/KOH (pH 6.8)) containing 5 mM MgCl 2 , 1 mM ethylene glycol-bis (b-aminoethyl ether), 10% glycerol, 0.5% SBTI, Trasylol (Aprotinon) 10 KIU units/ ml, 1 mM PMSF and 0.1% bacitracin at a concentration of 15 mg protein/0.5 ml. Various combinations of the detergents (described above) at concentrations ranging from 0.1 to 1% were added to the suspended membrane proteins under icecold conditions for 1.5 h at 41C. The reaction tubes were gently vortexed at 41C for a few seconds every 10 min. The samples were centrifuged at 15 000 r.p.m. for 45 min at 41C, and the supernatants containing the solubilized membrane proteins aliquoted in microfuge tubes (1 mg/0.2 ml) and stored at À701C. The specific binding of the solubilized membrane protein with the radio-labeled ligand was examined by a slight modification of published procedures (Naldini et al., 1990) . Briefly, aliquots of the solubilized membrane proteins, containing 100-150 mg of protein/tube, were preincubated for 30 min at 41C in HEMGI buffer containing 0.2% BSA and 5 mM dithiothreitol (DTT, Sigma), in the presence or absence of varying concentrations of the competing peptides. A 1000-fold excess of the homologous peptide was used for defining nonspecific binding. Radio-labeled gastrin peptide was then added to the tubes, and the samples incubated for 30 min at 221C. The bound radio-labeled gastrin peptide was separated from the unbound peptide by precipitating the bound protein gastrin complex with 0.5 ml of 25% poly (ethylene glycol) þ 0.1 ml of bovine g globulins (5 mg/ml), at room temperature (RT) for 5 min. The precipitate was collected and washed on 0.45 mm cellulose acetate filters (Schleicher and Schuell, Inc., Keene, NH, USA) using a Bio-Rad (Hercules, CA, USA) filter manifold under a vacuum pressure of 25 mm Hg, as described previously (Narayan et al., 1992) , by published methods (Naldini et al., 1990) . Radioactivity retained by the filters was determined with a Beckman Gamma 8000 scintillation counter at a counting efficiency of B70%. As a result of these preliminary studies, a combination of CHAPS and CHS (as described below) was determined to be most effective in solubilizing membrane proteins that retained the highest concentration of specific binding proteins for gastrin-like peptides (data not shown).
The crosslinked membrane preparations were solubilized at a protein concentration of 15 mg/ml with 0.75% (w/v) CHAPS and 0.15% (w/v) CHS (diluted from a 1.25% CHAPS/0.25% CHS (w/v) stock in 20 mM HEPES, pH ¼ 6.5, and 10% glycerol (v/v)), in HEMGI buffer containing the protease inhibitors described above. The reaction mixtures were stirred gently for 1 h at 41C. The addition of 10% glycerol to the solubilization buffer markedly improved the stability of the solubilized receptor, as published previously (Naldini et al., 1990 ). The reaction mixture was then cleared by ultracentrifugation at 100 000 g for 1 h and the supernatant was diluted with HEMGI buffer to a final concentration of 100 mg/0.1 ml, such that the final concentration of CHAPS was reduced to o0.2%. The aliquots of solubilized binding proteins, crosslinked to radio-labeled gastrin peptides, were then subjected to SDS-PAGE and autoradiographically developed as described above. In a few experiments, the membranes were subjected to binding with radio-labeled gastrin peptides in the presence or absence of increasing concentrations of the heterologous or homologous peptides, followed by crosslinking and solubilization, in order to determine the RBA of the differentially sized GBPs (separated by SDS-PAGE), for binding gastrin-like peptides.
Elution and enrichment of the crosslinked radio-labeled GBPs The solubilized membrane proteins, crosslinked with radiolabeled gastrin, were electrophoretically separated and sliced by a gel cutter (Pierce, Rockford, IL, USA) into B1 mm slices that were placed at the bottom of tubes and counted in a gamma counter. Gel slices associated with peak counts were subjected to protein elution by placing in dialysis tubes containing 1 ml of 0.2 M Tris/acetate (pH 7.4), 1% SDS, 100 mM DTT/0.1 g of wet polyacrylamide gel. The dialysis tubing was dialysed against 50 mM Tris/acetate (pH 7.4), 0.1% SDS, 0.5 mM sodium thioglycolate, for 12-16 h at RT. The gel pieces were then removed from the dialysis tubing, and the tubing further dialysed against several changes of 0.2 M sodium bicarbonate, 0.02% SDS. At the end of the dialysis, the eluted protein within the dialysis tubing was removed and lyophilized. This method allowed us to recover 70-80% of the radioactivity associated with the proteins within the gel slices before dialysis (data not shown).
Eluates from gel slices (representing similarly sized protein bands) from several gels were combined and lyophilized and reconstituted in HMEGI buffer at a concentration of B1-2 mg/0.2 ml. The reconstituted proteins of different sizes were electrophoretically separated and identified by Coomassie blue staining.
Identification of the 32-36kDa proteins by peptide mapping and database mining The enriched solubilized proteins, crosslinked to radio-labeled G1-17, were repurified by SDS-PAGE, and visualized by Coomassie blue staining. The protein bands of interest in the 32-36 kDa range were punched out from the gel with a Pasteur pipette into a microfuge tube. An area of the gel with no protein was similarly punched out as a trypsin control whereas one of the molecular weight markers was used as a positive control. The gel pieces in the microfuge tubes were then subjected to destaining with 50% methanol and 10% acetic acid for 1 h at RT Â 2 with constant shaking, followed by washing with 400 ml of 0.1 M NH 4 HCO 3 , pH 8.0, for 1 h at RT. The buffer was replaced with 0.5 ml 50% acetonitrile in 0.1 M NH 4 HCO 3 , pH 8.0 for 1 h at RT. The gel pieces were finally washed with 50 ml of 100% acetonitrile for 15 min at RT, followed by removing all the solvent and drying the gel pieces in a speedvac for about 15 min. The dried gel pieces were finally subjected to digestion with 10 ml of trypsin solution (0.02 mg trypsin/ ml in 25 mM NH 4 HCO 3 , pH 8.0, Promega Corp., Madison, WI, USA). After 15 min of incubation, 20 ml of NH 4 HCO 3 buffer was added and the capped tubes incubated for an additional 4 h at 371C in a dry air incubator. The gel eluates containing the trypsin-digested proteins were then carefully removed and frozen at À801C until further analysis.
